Impact of Widespread Cervical Cancer Screening

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 41, Issue 3, 2018, Pages 289-294

  Yang, Daniel X ^a,b   Soulos, Pamela R ^a,b   Davis, Brigette ^a,b   Gross, Cary P ^a,b,c   Yu, James B ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Yale Cancer Outcomes Policy and Effectiveness Research Center (COPPER)   (United States)

^c Departments of Internal Medicine Nephrology   (United States)

Author keywords

cancer screening; cervical neoplasms; HPV DNA test; incidence; Papanicolaou test

Indexed keywords

WART VIRUS VACCINE;

ADULT; AGED; CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER PREVENTION; CANCER SCREENING; CANCER STAGING; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; EARLY CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MORBIDITY; NATIONAL HEALTH ORGANIZATION; PAPANICOLAOU TEST; RACE DIFFERENCE; UTERINE CERVIX CANCER; VACCINATION; ADOLESCENT; CANCER REGISTRY; EARLY CANCER DIAGNOSIS; INCIDENCE; MASS SCREENING; MIDDLE AGED; PROCEDURES; UNITED STATES; UTERINE CERVIX TUMOR; VAGINA SMEAR; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; EARLY DETECTION OF CANCER; FEMALE; HUMANS; INCIDENCE; MASS SCREENING; MIDDLE AGED; SEER PROGRAM; UNITED STATES; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; YOUNG ADULT;

EID: 84955587768     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0000000000000264     Document Type: Conference Paper

References (61)

1. Moyer VA. US Preventive Services Task Force. Screening for cervical cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;156:880-891. W312.
2. Clarke EA, Anderson TW. Does screening by "Pap" smears help prevent cervical cancer A case-control study. Lancet. 1979;2:1-4.
3. Vesco KK, Whitlock EP, Eder M, et al. Screening for Cervical Cancer: A Systematic Evidence Review for the US Preventive Services Task Force. Rockville, MD: Agency for Healthcare Research and Quality (US); 2011.
4. Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357:1579-1588.
5. Naucler P, Ryd W, Tornberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med. 2007;357:1589-1597.
6. Akers AY, Newmann SJ, Smith JS. Factors underlying disparities in cervical cancer incidence, screening, and treatment in the United States. Curr Probl Cancer. 2007;31:157-181.
7. Janerich DT, Hadjimichael O, Schwartz PE, et al. The screening histories of women with invasive cervical cancer, Connecticut. Am J Public Health. 1995;85:791-794.
8. Pierce Campbell CM, Menezes LJ, Paskett ED, et al. Prevention of invasive cervical cancer in the United States: past, present, and future. Cancer Epidemiol Biomarkers Prev. 2012;21:1402-1408.
9. McDougall JA, Madeleine MM, Daling JR, et al. Racial and ethnic disparities in cervical cancer incidence rates in the United States, 1992-2003. Cancer Causes Control. 2007;18:1175-1186.
10. Singh GK, Miller BA, Hankey BF, et al. Persistent area socioeconomic disparities in US incidence of cervical cancer, mortality, stage, and survival, 1975-2000. Cancer. 2004;101: 1051-1057.
11. Simard EP, Naishadham D, Saslow D, et al. Age-specific trends in black-white disparities in cervical cancer incidence in the United States: 1975-2009. Gynecol Oncol. 2012;127:611-615.
12. Ward KK, Shah NR, Saenz CC, et al. Changing demographics of cervical cancer in the United States (1973-2008). Gynecol Oncol. 2012;126:330-333.
13. Stokley S, Jeyarajah J, Yankey D, et al. Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014-United States. MMWR Morb Mortal Wkly Rep. 2014;63:620-624.
14. Kahn JA. HPV vaccination for the prevention of cervical intraepithelial neoplasia. N Engl J Med. 2009;361:271-278.
15. Chesson HW, Flagg EW, Koutsky L, et al. Modeling the impact of quadrivalent HPV vaccination on the incidence of Pap test abnormalities in the United States. Vaccine. 2013;31:3019-3024.
16. FDA approves first human papillomavirus test for primary cervical cancer screening. 2014. Available at: http://www. fda. gov/newsevents/ newsroom/pressannouncements/ucm394773. htm. Accessed October 15, 2014.
17. Nielsen C, Lang RS. Principles of screening. Med Clin North Am. 1999;83:1323-1337. v.
18. National Cancer Institute. Percent of women aged 18 years and older who had a pap smear test within the past 3 years by race/ ethnicity: 1987-2010. Cancer Trends Progress Report-2011/2012 update.
19. Dickinson LE. Control of cancer of the uterine cervix by cytologic screening. Gynecol Oncol. 1975;3:1-9.
20. Kegeles SS, Kirscht JP, Haefner DP, et al. Survey of beliefs about cancer detection and taking Papanicolaou tests. Public Health Rep. 1965;80:815-823.
21. Moss AJ, Wilder MH. Use of Selected Medical Procedures Associated With Preventive Care: United States-1973. Rockville, MD: National Health Survey; 1977.
22. Bloom B. Use of Selected Preventive Care Procedures: United States, 1982. Hyattsville, MD: US Department of Health and Human Services; 1986.
23. Surveillance, Epidemiology, and End Results (SEER) Program (www. seer. cancer. gov) SEERStat Database: Incidence-SEER 9 Regs Research Data, Nov 2011 Sub, Vintage 2009 Pops (1973-2009) >Katrina/Rita Population Adjustment <-Linked To County Attributes-Total U. S., 1969-2010 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2012, based on the November 2011 submission. Available at: http://www. seer. cancer. gov. Accessed February 1, 2014.
24. Park HS, Lloyd S, Decker RH, et al. Overview of the Surveillance, Epidemiology, and End Results database: evolution, data variables, and quality assurance. Curr Probl Cancer. 2012;36:183-190.
25. US Population Data-1969-2011. Surveillance, Epidemiology, and End Results (SEER) Program; 2013. Available at: http:// seer. cancer. gov/popdata/. Accessed February 1, 2014.
26. Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med. 2012; 367:1998-2005.
27. Yang DX, Gross CP, Soulos PR, et al. Estimating the magnitude of colorectal cancers prevented during the era of screening: 1976 to 2009. Cancer. 2014;120:2893-2901.
28. Plaxe SC, Saltzstein SL. Estimation of the duration of the preclinical phase of cervical adenocarcinoma suggests that there is ample opportunity for screening. Gynecol Oncol. 1999;75:55-61.
29. Lundin FE Jr, Christopherson WM, Mendez WM, et al. Morbidity from cervical cancer: effects of cervical cytology and socioeconomic status. J Natl Cancer Inst. 1965;35:1015-1025.
30. Cramer DW. The role of cervical cytology in the declining morbidity and mortality of cervical cancer. Cancer. 1974;34: 2018-2027.
31. Devesa SS, Silverman DT, Young JL Jr, et al. Cancer incidence and mortality trends among whites in the United States, 1947-84. J Natl Cancer Inst. 1987;79:701-770.
32. Tiwari RC, Clegg LX, Zou Z. Efficient interval estimation for ageadjusted cancer rates. Stat Methods Med. 2006;15:547-569.
33. Scarinci IC, Garcia FA, Kobetz E, et al. Cervical cancer prevention: new tools and old barriers. Cancer. 2010;116: 2531-2542.
34. Jemal A, Simard EP, Dorell C, et al. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst. 2013; 105:175-201.
35. Brinton LA, Hamman RF, Huggins GR, et al. Sexual and reproductive risk factors for invasive squamous cell cervical cancer. J Natl Cancer Inst. 1987;79:23-30.
36. Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine. 2006;24(suppl 1):S1-15.
37. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med. 1997;102(5A):3-8.
38. Ellerbrock TV, Chiasson MA, Bush TJ, et al. Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA. 2000;283:1031-1037.
39. Slattery ML, Robison LM, Schuman KL, et al. Cigarette smoking and exposure to passive smoke are risk factors for cervical cancer. JAMA. 1989;261:1593-1598.
40. Baylor NW. Approval Letter-Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant. In: Department of Health and Human Services, ed. 2006. Available at: http:// www. fda. gov/BiologicsBloodVaccines/Vaccines/ApprovedProduc ts/ucm111283. htm. Accessed October 15, 2014.
41. Franco EL, Cuzick J, Hildesheim A, et al. Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine. 2006;24(suppl 3):S3/171-S3/177.
42. Isidean SD, Franco EL. Embracing a new era in cervical cancer screening. Lancet. 2014;383:493-494.
43. Dempsey A, Cohn L, Dalton V, et al. Worsening disparities in HPV vaccine utilization among 19-26 year old women. Vaccine. 2011;29:528-534.
44. Mandelblatt J, Andrews H, Kerner J, et al. Determinants of late stage diagnosis of breast and cervical cancer: The impact of age, race, social class, and hospital type. Am J Public Health. 1991;81: 646-649.
45. Ferrante JM, Gonzalez EC, Roetzheim RG, et al. Clinical and demographic predictors of late-stage cervical cancer. Arch Fam Med. 2000;9:439-445.
46. Mitchell JB, McCormack LA. Time trends in late-stage diagnosis of cervical cancer. Differences by race/ethnicity and income. Med Care. 1997;35:1220-1224.
47. Feldman S. Human Papillomavirus testing for primary cervical cancer screening: is it time to abandon Papanicolaou testing JAMA Intern Med. 2014;174:1539-1540.
48. Saraiya M, Berkowitz Z, Yabroff KR, et al. Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs. Papanicolaou testing alone: what screening intervals are physicians recommending Arch Intern Med. 2010;170: 977-985.
49. Wright TC Jr, Stoler MH, Behrens CM, et al. The ATHENA human papillomavirus study: design, methods, and baseline results. Am J Obstet Gynecol. 2012;206:46. e41-46. e11.
50. Wright TC, Stoler MH, Behrens CM, et al. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol. 2015;136:189-197.
51. Weinmann S, Williams AE, Kamineni A, et al. Cervical cancer screening and follow-up in 4 geographically diverse US health care systems, 1998 through 2007. Cancer. 2015;121:2976-2983.
52. Cuzick J, Myers O, Hunt WC, et al. A population-based evaluation of cervical screening in the United States: 2008-2011. Cancer Epidemiol Biomarkers Prev. 2014;23:765-773.
53. Schiffman M, Wentzensen N. Transitioning to a new era in cervical cancer screening. Gynecol Oncol. 2015;136:175-177.
54. Sauer AG, Jemal A, Simard EP, et al. Differential uptake of recent Papanicolaou testing by HPV vaccination status among young women in the United States, 2008-2013. Cancer Epidemiol. 2015; 39:650-655.
55. Woolf SH, Harris R. The harms of screening: new attention to an old concern. JAMA. 2012;307:565-566.
56. Esserman LJ, Thompson IM Jr, Reid B. Overdiagnosis and overtreatment in cancer: An opportunity for improvementemerging overdiagnosis and overtreatmentviewpoint. JAMA. 2013; 310:797-798.
57. Gross CP. Cancer screening in older persons: A new age of wonder. JAMA Intern Med. 2014;174:1565-1567.
58. Bower JK, Schreiner PJ, Sternfeld B, et al. Black-White differences in hysterectomy prevalence: The CARDIA study. Am J Public Health. 2009;99:300-307.
59. Whiteman MK, Hillis SD, Jamieson DJ, et al. Inpatient hysterectomy surveillance in the United States, 2000-2004. Am J Obstet Gynecol. 2008;198:34. e31-34. e37.
60. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: Terminology for reporting results of cervical cytology. JAMA. 2002;287:2114-2119.
61. Morgenstern H. Ecologic studies in epidemiology: concepts, principles, and methods. Annu Rev Public Health. 1995;16:61-81.